• In early August 2026, Aramark’s board approved a past quarterly dividend of US$0.12 per share, and Aramark Collegiate Hospitality announced a long-term partnership with the University of Colorado Colorado Springs to operate and enhance campus dining, retail, catering, and hospitality programs.
• This combination of continued cash returns to shareholders and Aramark’s first partnership within the University of Colorado System highlights how the company is tying capital discipline to expansion in education-focused hospitality.
• We’ll now examine how the new University of Colorado Colorado Springs partnership influences Aramark’s existing investment narrative and growth drivers.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

Aramark Investment Narrative Recap

To own Aramark, you need to believe in its ability to turn long-term service contracts in education, healthcare, and venues into steady cash flow while protecting thin margins. The new University of Colorado Colorado Springs (UCCS) contract and the continued US$0.12 dividend do not change the biggest near term swing factor, which remains cost control in a tight labor market, nor the key risk of contract economics coming under pressure in cyclical client sectors.

Among recent developments, the UCCS partnership stands out because it directly reinforces one of Aramark’s core growth drivers: higher education wins with broad, multi-year scope. Like the earlier 15 year University at Albany agreement, this deal adds another campus ecosystem where Aramark can layer in technology, wellness focused menus, and community programming, all of which tie back to the existing catalyst of expanding education-focused hospitality while trying to sustain attractive contract margins.

But while the contracts look attractive on paper, investors should be aware that rising labor and healthcare costs could still...

Aramark's narrative projects $23.8 billion revenue and $798.9 million earnings by 2029. This requires 7.0% yearly revenue growth and about a $441.9 million earnings increase from $357.0 million today.

Uncover how Aramark's forecasts yield a $59.44 fair value, a 6% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts assume earnings of about US$803.8 million on US$23.2 billion revenue by 2029, which is far more cautious than bullish views and may be revisited as deals like UCCS and Aramark Nexus data center opportunities evolve.

Explore 2 other fair value estimates on Aramark - why the stock might be worth as much as 6% more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Aramark research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Aramark research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Aramark's overall financial health at a glance.

Contemplating Other Strategies?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• AI is about to change healthcare. These 42 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• The future of work is here. Discover the 36 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Find 51 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.